Q4 2019 Earnings Call
[music].
Ladies and gentlemen, thank you for standing by and welcome to the Elanco Animal Health Inc. Q4, 2019 earnings Conference call.
At this time all participants are in listen only mode. After the speakers presentations there will be a question answer session.
Ask a question during the session you will need to press star one on your telephone.
If you require any further assistance. Please press star zero I would now like to hand to hand conference over to your speaker today, Jim Griffey head of Investor Relations. Thank you. Please go ahead, Sir Thanks, Chris Good morning. Thank you for joining us for Elanco Animal Health Q4, 2019 earnings call I'm, Jim Herve head of Investor Relations joining me.
On today's call, our Jeff Simmons, our President and Chief Executive Officer, Todd Young, our Chief Financial Officer, and Kt Grissom from Investor Relations. During this conference call, we anticipate making projections and forward looking statements based on our current expectations. Our actual results could differ materially due to a number of factors, including those listed on slide two.
And though as outlined in our latest forms 10-K in 10-Q find <unk> filed with the Securities and Exchange Commission. The information we provide about our products and pipeline is for the benefit of the investment community. It's not intended to be promotional and is not sufficient for prescribing decisions you can find our press releases our press release the slides referenced on this.
Call and an investor workbook on Elanco dotcom, the slides and press release also contained further information about the non-GAAP financial measures that we to does that we discussed today. During this call. After our prepared remarks, we'll be happy to take your questions I'll turn the call over now to Jeff to provide highlights thanks Jim.
Good morning, everyone. This quarter marks the close of our first full year as a public company, we delivered on our strategy advancing our pipeline utilizing our portfolio approach to support our customers through unprecedented disease and drought and furthering our productivity efforts to deliver margin improvement.
All while evaluating and integrating strategic acquisitions that we believe will increase Atlantic goes competitiveness and value for our customers for the long term.
2019 wasn't eventful year, Eddie Linco and I want to thank our employees for their resilience and their determination during this exciting time and our company's history.
Let's begin with the highlights for 2019 on slide three.
Our financial results for the year are in line with our previously issued guidance.
Full year sales of 3.071 billion.
Is that the low end of the sales guidance range, while adjusted diluted earnings per share of a dollar six is at the midpoint of EPS guidance range for the full year Elanco core revenue grew 3% at constant currency and our targeted growth categories grew 7%.
We delivered significant improvements in our gross margin, which increased 220 basis points compared to the prior year.
Despite incurring a number.
Of new expenses as a result of being a public company, we improved our adjusted EBITDA margin 60 basis points to 21.6%.
We are on track.
Toward our long term margin goal of 31% for Standalone Elanco in 2023.
We also made tremendous progress building, our standalone capabilities, which are fit for purpose as an independent animal health company.
First we substantially completed two restructuring activities to streamline our commercial R&D and manufacturing operations.
We also went live on our new HR system Workday.
We have exited 65% of the transition service agreements with Lilly.
And we have locked the scope of our independent S&P system that we expect to go live and early 2021.
We are on track to stand up independent new ankle.
Finally, the bare animal health acquisition is progressing nicely.
Thus far in 2020 this year, we received regulatory approval in China, Ukraine and Turkey.
We are gaining increasing clarity on the regulatory front and other jurisdictions and have reached agreements to divest for products, bringing total divested revenue near the 120 to 140 million, we expect to divest.
Additionally, we completed all necessary capital markets activities for debt and equity to finance the transaction.
Our three stream approach to running Elanco standup independent dealer Banco and integrate Bayer is working.
Now, let's take a closer look at our sales performance on slide four.
For those of you that have followed our business since the IPO you become accustomed to the quarterly variability across our product categories and.
In Q4 is no exception.
To put this quarter into context, it's helpful to remind ourselves of the results. We saw in the comparison period in 2018.
Which is shown in the first column.
I'll, let Todd provide the details, but you can see that the growth rates in our two companion animal categories are largely mirror images across the two years.
We highlighted events that amplified the growth and disease prevention in 2018.
Which now provide difficult comparison.
And other events that depressed the growth and therapeutics in 2018, now, creating a more favorable compares.
When we adjust for these events the underlying performance across our categories is on track with our expectations.
A 7% growth in our targeted growth categories for full year 2019 is reflective of the fundamental strength and performance of our business.
The difficult comparison in companion animal disease prevention belies the strong underlying performance in that category led by crude deleo and interceptor plus.
We recently completed a first of its kind study in collaboration with IDEXX that found 85% of dog parks and 30 major metro areas had at least one dog test positive for internal parasites.
Of the more than 3000 samples collected by client owned dogs in the study one in five had parasites.
This finding illustrates two key issues first the need for increased Pat owner awareness of the exposure to parasites and second the importance of products that protect their pets from all types of worms.
This study reinforces the value of interceptor plus.
Which is indicated for the five different kinds of internal worms, where others are not.
And when used in conjunction with crude Leo.
Also it protects against fleas and ticks, giving the broadest coverage available.
The ruminants and swine categories also positively impacted by some comparison events, particularly the initial resolution of manufacturing issues at our sterile injectables supplier in 2019 as well as sales of Posilac inventory.
To summarize 2019 was a challenging year.
With a number of external events that emerged throughout the year.
Including African swine fever supply challenges drought changing producer use of certain products from policy and trade and the entrant of a new generic competitor.
Despite these challenges we grew core sales.
We increased margins and continued to build the foundation for long term value creation.
2019 illustrates the importance of having a portfolio diversifying across species and geographies and having a sole focus on animal health.
Elanco is well positioned on all fronts, and we believe will be even stronger with the addition of their animal health.
Let's move to slide five and review, how we executed on the three pillars of our strategy in 2019.
First on innovation.
Our strategy is built on launching with excellence progressing our internal pipeline and complementing our internal pipeline with external opportunities.
Our new products continue to fuel our growth increasing 60% year.
Year over year in 2019.
This group contributed over 400 million in sales and represented 14% of our total sales for the year.
You can see the growth trajectory of these products in constant currency on slide 15.
We're also pleased to announce.
That we met the goal of putting 25 antibiotic alternative programs into development by 2020.
A commitment we made at the White House Forum on antibiotic stewardship and 2015.
But I believe most importantly in the area of innovation.
When we combine elanco with bear will have 25 launch equivalents planned to go into the market between 2020 and 2024.
This will open the next era innovation growth free Linco.
Now in the portfolio.
For the year, our targeted growth categories delivered 7% growth.
And represented about 61% of our total sales.
These are attractive market segments as we've discussed in the past where a portfolio of products address important customer needs.
We continue to see outsized growth in physical retail and E commerce for the us in pets.
Although these alternative channels are smaller than the vet channel they are growing significantly.
Hey, long Elanco Parasiticides.
Our growing faster than the overall market in these alternative channels.
And Gallup brand is our second largest product in these channels.
Our sales have more than doubled in the alternative channels over the past two years and we remain very optimistic about the future of expanding our reach and these channels and meeting pet owners, where they want to shop.
Now turning to our third pillar productivity.
The continued improvement in our gross margin in 2019 as a result of the comprehensive productivity agenda throughout our company.
In 2019, our manufacturing organization delivered 70 million in cost savings and cost avoidance.
Recall about 65 million in savings was delivered last year in 2018 and the team has all the actions in motion to deliver the expected 215 million in savings.
From 2018 to 2020 that we previously share.
Let me be clear our productivity roadmap is on track.
Remember that often actions take taken in the current period takes some time to make their way through the income statement.
In 2019, we took actions that we expect will continue to improve profitability in the future and they are one we negotiated procurement savings across the value chain.
Also we continue the reduction of contract manufacturers now at Ninebc Ammos down from 100 at the end of 2018.
We also ceased operations at large would Iowa vaccine.
And we'll see China pie facilities.
And we implemented technical improvements and lean manufacturing principles that drove tighter expense management across several sites.
Beyond manufacturing, we announced the sale of our our core research and development facility in Canada.
And Elanco will shift this important capability into other existing R&D facilities.
Finally, we continue to make great progress in standing up the independent Elanco as I mentioned earlier.
Overall, our productivity agenda is delivering and we're pleased with the progress achieved in 2019.
As I indicated in our 2020 guidance call.
We are in an attractive industry.
Elanco is moving with speed and agility.
Our growth is durable and resilient.
And the bare transaction holistically, considering all aspects of the deal continues to track above our expectations.
Now I'll turn the call over to Todd to provide more color on our Q4 results and financial guidance for 2020.
Thanks, Jeff Slide six summarizes our presentation of GAAP results, while slide seven describes the items considered a need adjusted financials.
Slide 16 to 21 in the appendix provides a summary of the adjustments made to the GAAP results to arrive at our adjusted presentation.
I'll focus my comments on our adjusted measures to provide insights into the underlying trends in our business. So please refer to todays earnings press release for a detailed description of the year on year changes in our fourth quarter GAAP results.
Looking at the adjusted measures on slide eight you'll see a total ankle revenue decreased 2% in the quarter on a constant currency basis total annual revenue decreased 1% or core local revenue increased 1% at constant currency.
Gross margin as a percent of revenue was 47.9% decline compared to the fourth quarter of last year, driven by product mix and foreign exchange headwinds in Q4, 2019, which were largely offset by continued productivity gains and positive price.
As we've indicated our long term margin expansion will be driven primarily by the benefits of cost facing productivity measures and price increases we expect product mix will not be a significant driver margin over time, although mix may impact margin given periods as we see in Q4.
Our year to date gross barges, 52.1%, a 220 basis point improvement over 2018. This improvement was driven by our continued productivity agenda and positive price, partially offset by mix.
Operating expenses increased 3% in the fourth quarter marketing selling and administrative expense was $186 million flat with the prior year, resulting from additional costs from acquired businesses in the current year, primarily aritomo and incremental expenses as a result of operating as a public company also.
By strong expense management throughout the organization.
R&D expense increased 10% to $67 million or 9% of revenue, reflecting additional costs from acquired businesses in the current year, including era, Tata and protect.
Investments in the expanded pipeline increased costs from R&D infrastructure investments.
Operating income declined 12%, reflecting the impact of sales gross margin of operating expense results I just described.
Full year operating income increased 4%.
At the bottom line Q4, adjusted net income decreased 70% $87.8 billion of the Q4 effective tax rate was 11.1%.
For the full year, our adjusted EBITDA margin improved 60 basis points to 21.6%, reflecting the execution of our productivity agenda, even with the numerous revenue headwinds and the additional expenses, resulting from acquisitions and operating as an independent company.
Moving to slide dive, let's take a look at the effective price rate and volume on revenue growth.
Effective foreign exchange rates, a core revenue was a 1% headwind overall price grew 2% or volume declined 1%.
All the slide you can see the breakdown of revenue across our four categories I will focus on constant currency growth, starting with companion animal disease prevention, which includes parasiticides and vaccines.
Revenue in this category declined 14% in the quarter, 13% from volume and 1% from price recall that there were several factors in the prior year that created a challenging comparison in this category in Q4 2018, we saw stock you have vaccines from new customer agreements, we sold the remaining inventory.
Aerostar, and we saw increased customer purchases of disease prevention products to achieve desired incentive levels across all companion animal since the supply of Gallup Brown was constrained.
The current year decline was driven by these comparison period issues as well as continued declines in older generation Parasiticides, partially offset by continued uptake in growth of interceptor plus aired credential.
As Jeff indicated these products continue to perform well with strong underlying demand after clinic level.
Moving to companion animal Therapeutics revenue increased 34% the quarter, 27% for volume and 7% from price growth is driven by the continue the uptake of Gallup crabs of a favorable comparison from the prior year due to golfer back orders in 2018 as well as the additional sales for into.
Most of those pseudo for marathon.
Turning to our food animal portfolio of future protein health revenue grew 2% in the quarter, 3% from price also by 1% decline in volume.
Growth in this category was driven by the continued uptake of our auto portfolio poultry vaccines and nutritional products, partially offset by the impact from changing policies in Asia as well as producer rotation.
[noise] ruminants in swine revenue increased 3% in the quarter driven by a 2% increase in volume at a 1% increase in price.
The growth was primarily driven by the sales of Pawluk inventory and partial resumption of sales for sterile injectable product, which had been suspended due to quality issues at the contract manufacturer.
Growth was partially offset by the continued impact of African swine fever in Asia, changing use producer use of pay lane and to a lesser extent decreased revision sales.
Note that for the sterile injectables the suppliers now we filling the supply chain for the various products, we expect and supply chain to be replenish during Q1 and into Q2 of 2020.
Revenue from strategic exits decreased 54% in the quarter recall that thoroughly to activities in this category.
The contract manufacturing for VI, Evan production of human growth hormone for Lilly.
Slide 10 provides more details of our overall performance in the U. us and internationally.
International business grew core revenue, 5% in the quarter, while the U.S. business declined 3%, primarily driven by the results I discussed earlier in the companion animal disease prevention category.
Now turning to our financial guidance for the full year 2020 on slide 11, which is unchanged for the original guidance. We provided on January 10th of 2020.
As we did initially the guidances for the Standalone will anchor is does not include any revenue or expenses from bear animal health.
It includes full year revenues for all it go products, including announced divestitures or other products that may be divested.
And it does not consider any of the financing elements of the bare transaction such as additional shares issued or interest expense from additional debt.
It does include the costs associated with standing up a waco and integration planning for the bare acquisition consistent with our 2019 results.
We will provide updated 2020 guidance for the combined company after the transaction closes.
For 2020, we expect total revenue between $3.05 billion of $3.11 billion.
Excluding strategic exits we project core revenue of $3 billion to $3.6 billion, we expect strategic effort exit revenue to continue to decline year on year.
GAAP earnings per share are projected to be four cents to 16 cents, while adjusted EPS are expected to be a dollar a nine cents to $1.16 cents.
Slide 11 also shows the foreign exchange rates used for our top five international currencies. These rates constitute approximately $25 million of revenue headwind compared to 2019.
No. The view US dollar has continued to strengthen compared to these rates.
This guidance reflects the continued execution of our productivity and margin improvement strategy throughout our operations with constant currency adjusted EPS growing at a faster rate than sales.
Turning to slide 12, you can see the items removed from GAAP Bcf to arrive at our adjusted EPS guidance.
For reference we have included in the appendix a walk forward of our estimated share count considering the common shares and tangible equity units issued in January as well as the shares to be issued to bear at close again, our current guidance does not reflect the impact of these transaction related items, let me turn.
Things back to just to summarize.
Thanks Todd.
Let me first take a moment to comment on the Corona virus.
Our number one focus is our employees and we're thankful that all of our employees are healthy and safe.
We've not seen immaterial impact to our business at this point the situation remains fluid and a transcends or industry.
Recall that China is approximately 2% of our total sales we are monitoring several key areas first restrictions on travel and in person sales rep interactions with customers.
We are leveraging virtual and online approaches to maintain dialogue.
Second local logistics.
Excuse me and the ability to move products throughout China to this point, we've not seen a material impact on this front.
And third we'll be watching the flow of product into and out of China.
We have regional manufacturing operations in China, and we utilize several China based contract manufacturers.
Our product flows into the market have not been interrupted in any significant way.
As we have safety stock throughout our supply chain that enables us to minimize impacts from short term supply disruptions.
Again, we are monitoring the situation closely and we will update the assessment for our business as appropriate.
In closing, we take stock of 2020 and beyond.
There are many things that excite us the body language position right now in this terrible industry first our new products are performing well and bring momentum into this year.
They are early in their life cycles, we are investing in them and they continue to be important drivers of growth.
Second as we previously shared we plan on launching new products in 2020, such as experience and new fat feed additive for cattle.
A novel Interleukin 10 product for poultry that can be used in no antibiotic ever production approaches where there is significant unmet need and we continue the geographic and label expansion of products like Gallup brand and critically ill.
And we have a robust pipeline as I've mentioned, including 25 potential launch equivalents for the combined new company throughout 2024.
Our margin expansion efforts are increasing our profitability with continued improvement ahead of us.
The fundamentals of our into industry are also favorable with persistent demand for animal protein and a dynamic companion animal sector.
And we're progressing to a mid year close on bear animal Health acquisition, we believe the combined company.
We'll be positioned for leadership and all the channels that matter to farmers veterinarians and pet owners.
With all these elements that I just mentioned I believe that Elanco stands is one of the companies with the most potential to create value for our customers society shareholders and other stakeholders.
Now I'll turn it over to Jim to moderate acuity.
Thanks, Jeff we'd like to take questions from as many people as possible. So try to limit your questions to to for a single question with two parts are Chris can you. Please give instructions and take the first question.
At this time I would like to remind everyone in order to ask your question Press Star then the number one on your telephone keypad.
Your first question comes from Michael Risking of Bank of America. Your line is open.
Great. Thanks for taking the question guys I want to start on the bare transaction you made a number of comments in the last couple of weeks and reiterated that today that it's tracking above expectation and things are going well with the underlying business. The performance of the conversation with regular et cetera.
It's really going to would have a deeper in that in terms of how much better. It's looking than you expected. What it is that that's getting you really decided relative to the initial plan you laid out for us in August of last year.
What have you seen in the in the feedback from channel from customers. What have you seen as you've gotten deeper and now that it's been about six months since those.
Is that initial announcement.
And then I've got follow up.
Sure. Michael This is Jeff. Thank you for the question.
Yes, so as I shared at the conference isn't and also with the guidance call, we'd be very clear I'm going to look at this holistic really across many streams of this transaction. We looked at this transaction in many streams with many options many levers to achieve the value that we need to for our shareholders and for our customers. So if I just take each one of these I'll just.
Highlight first.
There will announce their earnings next week on the 27th I believe in February but as we look at their performance.
In 2019 relative to our due diligence assumptions and findings we feel very good about that being validated with this year's performance by bear I also think secondly, as you look at the trends as we just mentioned and you look at alternative channels.
We feel very good also that allots cheese devens since August when you look at the channel when you look at distribution and look at it beyond just parasiticides in the us but look at it globally.
And we look at launches like Sureste own advantage in into capabilities and can come to Asia.
We see those trends actually emerging more positively than even what may be we had assumed from our seat in August. So thats. Another factor that I think we look at I think the other is divest response I think.
You can't do this one by one but we've been very diligent on looking at this relative to we believe this is in and not an or it starts and ends with the veterinarian. The veterinarian is absolutely vital to our business.
And it will be even as vital or more vital as we go forward and it's our job to enable them to not only be successful in the clinic could be successful in reaching a lot of pet owners that are either not coming into their clinic or that they're not compliant not using the products appropriately. So when we model. This when we look at it and when we communicate with.
Thats, we feel very good then I think the other pieces are pretty obvious.
The financing that's occurred so far on the reaction to the financing we have both the equity in the debt.
Details that we believe the reaction to this is also a very positive signal to the story into the strategic nature and the value proposition that we give the marketplace.
That was very favorable relative to two what we wanted in our expectations.
And then I think on anti trust to and I'll, just close by saying that we.
I have deals in place for.
Four key assets that we've announced and there'll be a couple remaining that will be more regional in nature and add those those will follow here shortly but this 120 to 140 million of total revenue on the combined company. We continue to feel very good that we're coming up on that number.
Her which means that we're coming due to close of what we believe is key.
Clearances on countries that are key like China, our emerging well and so we're on track and then lastly, just to stand up to stand up is going well remember that even with antitrust clearances, we won't close on this asset until mid year, even if we have antitrust clearances, because we need to.
I had the Tcs system set up and we move it over to Todd as we've mentioned so putting all that in place I feel very good while the company is running three streams very well we're running the company, we're delivering results and we're making great progress center stand up as an independent company Lilly So long answer, but I know.
Lot of people have an interest in this holistically, we feel very good better than we did originally with our expectations. Mike You said you had a follow up.
Great No I appreciate all that color Jeff.
Second question is on another topic that we've got.
We see a lot of focus on as the Simparica trio launch that's expected no wait or one Q or twoq.
Probably the biggest event, we've talked about animal health for the last several months what are your expectations for how to respond to this how do you prepare for it I mean, you talked a lot about the strength in CRE Deleon interceptor, and you mentioned that.
The dog parts study conducted with IODEX.
Sort of what are the conversations you're having with Thats ahead of that have you taken any proactive steps in terms of pricing or any work with your distributors to ensure that you're well saturated the market for that way before the competing product comes in.
Because you weigh on the road map here.
Yes, Michael Thank you and you know we've got a lot of discussions I'll talk about our our game plan, primarily right. So no surprise here relative to our expectations will be relaunches IPO in late 17, 18, we had highlighted very clearly that there would be likely an entry to the market before before us we look at this holistic.
We look into the parasiticide market one globally to holistically across all channels. We look at all the different segments I think that anytime innovation comes in the market has a tendency to expand because innovation creates expansion in markets better ease of use for customers and so I.
I think we keep we keep our eyes first on the whole market and not one sliver in one country now.
Within that I cannot emphasize enough that we feel very good about our premium position today with a portfolio we have.
I always start with Credentialing interceptor, plus but when you look at what we have across our portfolio even products like try faxes in what that does with people are worried about fleas and the different segments and what we're doing with the channel and we believe our position has never been stronger Holistically when you compare ourselves.
To our position in 2018 in 2017.
Now when I look at again I think it's important this study that we rolled out at via Max and we're rolling out in the marketplace to really emphasize that you now with with US and IDEXX studies never really been done like this it's a first of its kind 30 metro areas. You know, it's creating awareness of parasites, it's creating awareness.
Of all five worms that matter and one in five dogs, having that concern or having their presence. That's a big deal. That's that's been a big launch for us in the marketplace and today Interceptor plus is the primary product. They can do that our focus is going to be heavily around we're not going to allow pet owners to move to less coverage.
As they go forward and that will be our main interaction with with that with veterinarians. So like our strategy like our portfolio and we like our pipeline Michael as we go forward.
This is you're going to see a string of innovation from us in this space as we go forward and that string of innovation is going to move both across coverage new innovation, but also the ability to move channels and as I said when you put berni Lanka together, we'll have more exciting stuff going on in this space and we have ever had in the history of our.
Our boat combined companies. So that's I like our strategy like our portfolio and I like our future and pipeline as well.
Okay, I'm just going back to thanks, Mike Kristen we take next question.
Your next question comes from Chris Shaw of JP Morgan.
Your line is open.
Hi, This is actually Caterina on for Chris. Thank you for taking your questions. After the first question is can you provide a little bit more color on the quarterly gaining of gross margins. In 2020 is the gross margin progression. We saw in 2019, a decent way to think about 2020 or should we think about more consistent margins quarter to quarter.
Then my second question is on Galperin can you just help frame the potential size of the product where are we in terms of the penetration for cainiao noise and is there potentially somewhere down the line and opportunity for cats for the product. Thank you.
Good.
Generator. Thank you for your question with respect to gross margin in 2020, our quarterly phasing generally consistent as you see from this year, where the companion animal business on the parasiticide seasons are usually wait to wander into Q2 of where during Q4, you see the growth in our.
International of future protein to the health category.
So with that you have the margin.
Movements over the course of the quarter. So we still feel confident in this gross margin expansion that we've laid out for investors, including a 1000 basis points over five years with a generally being linear much like we saw this year with the 220 basis points, we're expecting a good growth in gross margin of 20 Twond.
Okay.
I think from a phasing perspective this year's phasing is a reasonable assumption for 2020.
Jeff talked about calibre, yes, so look I would start again with the pain market. I mean, we we have definitely very special product care and Gallup plant. It's grown significantly every year that we've had it and that's been part of our strategy and as you look at you know moving forward. There's no question that lifecycle management is one of the.
Elements to grow this market.
Cats is one of those as well as just looking to ease of use looking at expansion of geography would be another one beyond lifecycle management I think the big one now is in our and our our team here in the us and we're doing it in Europe as well is we have a program called coast, which is actually just increasing awareness.
Yes from pet owners on the understanding of of in our dog coming on with an early onset of away and that's important and about one out of six dogs has away, but tell you know and just like Parasiticides compliance and actually diagnosis is absolutely key and there will be devices down the road that we believe.
In other mechanisms to actually increase the diagnosis of away and then I would say that to you know movie NIS two more of a first line treatment for second line is another priority that we have as we see that this is a very safe the safest product in this and his segment to use so first line treatment is.
Maybe one of the biggest ones in the short term to continue to increase expansion I won't define the side what I will say is we're looking at overall pain and we've got on COO, which is approximates command very nice that's doing extremely well as as well as say you know products that have come from from Arizona that we feel very good about as while most seat as.
Doing well out of the gate so.
Again, continuing to work on the holes.
Pain area globally with our entire portfolio and we see this is one of the more attractive faster growing segments and the Pat and the pet side of our business.
Chris next question.
Your next question comes from that of Jacob of UBI US Your line is open.
Hello. Thank you so much for taking my question.
The two if I may number one.
As it relates to a buyer and your diligence that you've been continuing to conduct.
Wondering if you could provide any kind of color into the pipeline assets.
The eight assets that you highlighted before what are some of those assets what are the mechanisms what areas are they specifically for any color would be appreciated and then tied to that wondering when and what the status of your triplet.
Parasiticide product is.
Is that something that could come to the market by 2021 timeframe.
Any color would be appreciated thank you.
Yes, good questions. Let me just to highlight we are in the mode of.
We would call integration and Bayer would call separation with anti trust.
Guidelines, there will be some limitations. So we we entered with our due diligence assumptions now we're working through the stage of integration and separation for them and the still clean rooms, there's still some constraints.
And I'll be limited on even my access and details to be able to highlight what we've said is we like the eight development projects on their complimentary as you can see by even our anti trust work. So you can make that conclusion, there was a nice blend between the livestock and companion animal piece and we believe that they enter into some error.
He is that we're not into at this stage.
That will be complimentary to us that's really all I can say and then I think as you do the math of the eight development projects and a 36 or the that we have and you put put them together and ireton as assets I, we're really trying to add more color by saying, we'll have 25 launch equivalents, which are the problem lies candidates in.
The pipeline and Thats, a robust level of innovation that will be launching between this year and 2024.
Which are these 25 launch equivalents and in those would be approximately five from Bayer when you probably lies.
I'll highlight that and within that there will be a string of innovation in the parasiticides space will give anymore color than that than to say that will be an innovator in here and as we've said all along.
The intention here is to do three things every time, we launch into a market like parasiticides add to the portfolio be first in class or be best in class.